Robert H. Te Poele
London, ENG SM25GP, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 19, 2025
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2024
HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.
Journal: Journal of medicinal chemistry
Published: April 05, 2023
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.
Journal: Hepatology (Baltimore, Md.)
Published: July 31, 2019
Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.
Journal: Journal of medicinal chemistry
Published: December 23, 2016
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Journal: Molecular oncology
Published: December 06, 2016
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2012
Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.
Journal: Cancer research
Published: December 24, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026